Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies

被引:5
|
作者
Chen, Mu-Hong [1 ,2 ,4 ]
Cheng, Chih-Ming [1 ,2 ,4 ]
Li, Cheng-Ta [1 ,2 ,4 ]
Tsai, Shih-Jen [1 ,2 ,4 ]
Lin, Wei-Chen [1 ,2 ,4 ]
Bai, Ya-Mei [1 ,2 ,4 ]
Su, Tung-Ping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Psychiat, 201, Sec 2, Shih Pai Road, Taipei 112, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Fac Med, Div Psychiat, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Inst Brain Sci, Taipei, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Psychiat, Taipei, Taiwan
关键词
Treatment-resistant depression; Low-dose ketamine infusion; Repetitive transcranial magnetic stimulation; ANTIDEPRESSANT EFFICACY; INTRAVENOUS KETAMINE; SUICIDAL IDEATION; PREDICTORS;
D O I
10.1016/j.psychres.2022.114749
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD). Methods: In the ketamine infusion trial, 48 patients with TRD were randomized to receive a single infusion of 0.5 mg/kg ketamine or normal saline. In the rTMS trial, 105 patients were randomly assigned to intermittent thetaburst stimulation (iTBS), 10-Hz rTMS, or sham stimulation. The 17-item Hamilton Rating Scale for Depression (HDRS) was administered. Results: The antidepressant effect was prominent at Day 7 postinfusion in the ketamine group but steadily accumulated with the treatment duration from Day 7 to 14 in the iTBS and 10-Hz rTMS groups, regardless of the level of treatment resistance (all p < .01). Low-dose ketamine infusion and iTBS exerted superior effects on suicidal symptoms (HDRS item 3) than the other three groups (p < .001). The antidepressant effect of iTBS/10Hz rTMS may persist for up to 3 months; however, the antidepressant effect of a single low-dose ketamine infusion did not persist over a month. Discussion: Both low-dose ketamine infusion and rTMS/TBS must be included in TRD treatment but may be applied in different clinical situations.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression
    Yonezawa, Kengo
    Uchida, Hiroyuki
    Yatomi, Taisuke
    Ohtani, Yohei
    Nomoto-Takahashi, Kie
    Nakajima, Shinichiro
    Mimura, Masaru
    Tani, Hideaki
    PHARMACOPSYCHIATRY, 2024, 57 (01) : 35 - 40
  • [22] Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial
    Moussavi, Zahra
    Uehara, Maria
    Rutherford, Grant
    Lithgow, Brian
    Millikin, Colleen
    Wang, Xikui
    Saha, Chandan
    Mansouri, Behzad
    Omelan, Craig
    Fellows, Lesley
    Fitzgerald, Paul B.
    Koski, Lisa
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [23] Low-dose ketamine infusion for labor analgesia: A double-blind, randomized, placebo controlled clinical trial
    Joel, Sam
    Joselyn, Anita
    Cherian, Verghese T.
    Nandhakumar, Amar
    Raju, Nithin
    Kaliaperumal, Ilamurugu
    SAUDI JOURNAL OF ANAESTHESIA, 2014, 8 (01) : 6 - 10
  • [24] Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: A double-blind, placebo-controlled study
    Kauffmann, CD
    Cheema, MA
    Miller, BE
    DEPRESSION AND ANXIETY, 2004, 19 (01) : 59 - 62
  • [25] The priming effect of repetitive transcranial magnetic stimulation on clinical response to electroconvulsive therapy in treatment-resistant depression: a randomized, double-blind, sham-controlled study
    Rotharmel, Maud
    Quesada, Pierre
    Husson, Thomas
    Harika-Germaneau, Ghina
    Nathou, Clement
    Guehl, Julien
    Dalmont, Marine
    Opolczynski, Gaelle
    Mirea-Grivel, Iris
    Millet, Bruno
    Gerardin, Emmanuel
    Compere, Vincent
    Dollfus, Sonia
    Jaafari, Nemat
    Benichou, Jacques
    Thill, Caroline
    Guillin, Olivier
    Moulier, Virginie
    PSYCHOLOGICAL MEDICINE, 2023, 53 (05) : 2060 - 2071
  • [26] Repetitive transcranial magnetic stimulation as adjunctive treatment for resistant OCD: A randomized double blind placebo-controlled trial (preliminary data and interim analysis)
    Mansur, C.
    Bernik, M.
    Cabral, S.
    Myczkowsky, M.
    do Carmo Sartorelli, M.
    Rumi, D.
    Rosa, M.
    Pridmore, S.
    Rigonatti, S.
    Marcolin, M. A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S195 - S195
  • [27] A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
    Paulo R. Shiroma
    Paul Thuras
    Joseph Wels
    C. Sophia Albott
    Christopher Erbes
    Susannah Tye
    Kelvin O. Lim
    Translational Psychiatry, 10
  • [28] A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
    Shiroma, Paulo R.
    Thuras, Paul
    Wels, Joseph
    Albott, C. Sophia
    Erbes, Christopher
    Tye, Susannah
    Lim, Kelvin O.
    TRANSLATIONAL PSYCHIATRY, 2020, 10 (01)
  • [29] Effectiveness of Repetitive Transcranial Magnetic Stimulation in Patients With Failed Back Surgery Syndrome: A Double-Blind Randomized Placebo-Controlled Study
    Bursali, Canan
    Ozkan, Feyza Unlu
    Kaysin, Meryem Yilmaz
    Dortcan, Nimet
    Aktas, Ilknur
    Kulcu, Duygu Geler
    PAIN PHYSICIAN, 2021, 24 (01) : E23 - E30
  • [30] Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial
    Croarkin, Paul E.
    Elmaadawi, Ahmed Z.
    Aaronson, Scott T.
    Schrodt, G. Randolph, Jr.
    Holbert, Richard C.
    Verdoliva, Sarah
    Heart, Karen L.
    Demitrack, Mark A.
    Strawn, Jeffrey R.
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (02) : 462 - 469